About Clopidogrel Bisulfate (Form 2) API
Therapeutic CategoryCardiovascular
CAS Number
120202-66-6
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted, Brazil DMF, EUDMF, Russia DMF, China DMF
Mechanism of Action
Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.
Indication
Plavix is a P2Y12 platelet inhibitor indicated for:
- Acute coronary syndrome
– For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and stroke.
– For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke. - Recent MI, recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the rate of MI and stroke.
Related APIs
Amlodipine Besylate
Cardiovascular
Apixaban
Cardiovascular
Bempedoic Acid
Cardiovascular
Clopidogrel Bisulfate (Form 1)
Cardiovascular
Clopidogrel Bisulfate (Form 2)
Cardiovascular
Dabigatran Etexilate Mesylate
Cardiovascular
Doxazosin Mesylate
Cardiovascular
Ezetimibe
Cardiovascular
Fondaparinux Sodium
Cardiovascular
Lacidipine
Cardiovascular
Losartan Potassium
Cardiovascular
Mavacamten
Cardiovascular
Metoprolol Succinate
Cardiovascular
Ramipril
Cardiovascular
Rivaroxaban
Cardiovascular
Tafamidis Free Acid
Cardiovascular
Tafamidis Meglumine
Cardiovascular
Ticagrelor
Cardiovascular
Treprostinil
Cardiovascular
Treprostinil Olamine
Cardiovascular
Valsartan
Cardiovascular
Atorvastatin Calcium (Amorphous And Form P)
Cardiovascular
Sacubitril-Valsartan
Cardiovascular
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
Is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk
-
ST-segment elevation MI (STEMI): 75 mg/day PO in combination with aspirin 162-325 mg/day and then 81-162 mg/day.
-
We offer Polymorph Form-2
-
Jamica, China, Canada, Chile and Russia
-
Meet with our product experts in one-on-one virtual sessions at https://api.drreddys.com/meet-api-experts or Write to us at [email protected].
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.